ReviewCritical reviews in oncogenesis2011
RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making.
Review in Critical reviews in oncogenesis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 98 citations in OpenAlex.
- Article
- Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1.Blood neoplasia · 2025Article
- Susceptibility of RUNX1 promoter rs2071029 polymorphism to adjuvant chemotherapy-induced neutropenia in CRC.Biomarkers in medicine · 2025Article
- RUNX transcription factors are essential in maintaining epididymal epithelial differentiation.Cellular and molecular life sciences : CMLS · 2024Article
- Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM).Blood cancer journal · 2024Article
- BloodChIP Xtra: an expanded database of comparative genome-wide transcription factor binding and gene-expression profiles in healthy human stem/progenitor subsets and leukemic cells.Nucleic acids research · 2024Article
- Article
- Article
- Control of focal adhesion kinase activation by RUNX1-regulated miRNAs in high-risk AML.Leukemia · 2023Article
- Article
- Prognostic value and immune characteristics of RUNX gene family in human cancers: a pan-cancer analysis.Aging · 2022Article
- Review
- Rearrangement processes and structural variations show evidence of selection in oesophageal adenocarcinomas.Communications biology · 2022Article
- Article
- Review
- Unfolded Protein Response in Leukemia: From Basic Understanding to Therapeutic Opportunities.Trends in cancer · 2020Review
- Comparison of mutational profiles and clinical outcomes in patients with acute myeloid leukemia with mutatedLeukemia & lymphoma · 2020Article
- Runx1 negatively regulates inflammatory cytokine production by neutrophils in response to Toll-like receptor signaling.Blood advances · 2020Article
- The Clinical, Molecular, and Mechanistic Basis of RUNX1 Mutations Identified in Hematological Malignancies.Molecules and cells · 2020Review
- Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Translocations and mutations in the core binding factor genes, RUNX1 or CBFB, are found in acute myeloid and lymphocytic leukemia, therapy-related myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, and in familial platelet disorder with predisposition to acute myeloid leukemia. Here we review the biochemical and biological properties of the normal Runx1 protein, discuss the nature of RUNX1 mutations in myeloid leukemia, their prognostic significance, and the mutations that cooperate or co-exist with them in these various diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.